A Clinical Study of CHT101 in CD70-Positive Relapsed or Refractory Hematological Malignancies

PHASE1RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

March 31, 2025

Primary Completion Date

March 31, 2028

Study Completion Date

March 31, 2028

Conditions

Peripheral T-cell LymphomaCutaneous T-cell Lymphoma (CTCL)NHL (Non-Hodgkin Lymphoma)

Interventions

DRUG

CHT101

CD70 UCAR-T

Trial Locations (1)

RECRUITING

Tianjin Medical University Cancer Institute & Hospital, Tianjin

All Listed Sponsors

collaborator

Nanjing Calmhome Cell and Gene Engineering Institute Co., Ltd.

INDUSTRY

lead

Tianjin Medical University Cancer Institute and Hospital

OTHER